Administration of Tobramycin in the Beginning of the Hemodialysis Session
Open Access
- 1 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 2 (4) , 694-699
Abstract
Background: Aminoglycoside antibiotic efficacy is related to peak concentration (Cmax) and postantibiotic effect, whereas toxicity is directly related to body exposure as measured by area under the serum concentration versus time curve (AUC). On the basis of pharmacokinetic simulation models, tobramycin administration during the first 30 min of high-flux hemodialysis achieves similar Cmax but significantly lower AUC and prehemodialysis concentrations compared with conventional dosing in the last 30 min of hemodialysis.Keywords
This publication has 20 references indexed in Scilit:
- Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysisJournal of Antimicrobial Chemotherapy, 2003
- Risk factors for toxicity in elderly patients given aminoglycosides once dailyJournal of General Internal Medicine, 1998
- The Pharmacodynamics of AminoglycosidesClinical Infectious Diseases, 1998
- Population Pharmacokinetics of GentamicinClinical Pharmacokinetics, 1992
- The Incidence of Aminoglycoside Antibiotic-Induced Hearing LossJAMA Otolaryngology–Head & Neck Surgery, 1990
- In Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic MiceThe Journal of Infectious Diseases, 1988
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987
- Hemodialysis elimination rates and clearance of gentamicin and tobramycinAntimicrobial Agents and Chemotherapy, 1984
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Vestibular Toxicity of GentamicinArchives of internal medicine (1960), 1978